Recent

% | $
Quotes you view appear here for quick access.

Financial News From Zacks Small Cap Research

  • The company reported cash and cash equivalents of $26.3 million as of March 31, 2016. Thus, following the most recent raise we estimate that ContraFect currently has cash and cash equivalents of approximately $53 million.

  • In 2016 for the ninth consecutive year, Chesapeake Financial Shares, Inc. has been included in the American Banker magazine listing of the “Top 200 Community Banks” in the United States, ranking #67 out of about 6,000 community banks. Chesapeake Financial Shares, Inc. (CPKF or the Company) is a financial holding company …

  • AYTU: Gearing Up To Launch Natesto; Bolsters Leadership Team; Pursues NASDAQ Listing Zacks Small Cap Research - Wed, Jul 20, 2016 2:00 PM EDT
    AYTU: Gearing Up To Launch Natesto; Bolsters Leadership Team; Pursues NASDAQ Listing

    Acerus Pharmaceuticals Corporation (ASP.TO) terminated the agreement relating to the commercialization of Natesto in the U.S. and Mexico with Endo Ventures Bermuda Limited (an affiliate of Endo International plc) (ENDP) on June 30, 2016. In April 2016 Aytu acquired the exclusive rights from Acerus Pharmaceuticals to market …

  • VBIV: A Differentiated Immunology Company With Multiple Near Term Value Drivers Zacks Small Cap Research - Wed, Jul 20, 2016 11:00 AM EDT
    VBIV: A Differentiated Immunology Company With Multiple Near Term Value Drivers

    VBI Vaccines, Inc. (VBIV) is a commercial stage biopharmaceutical company developing vaccines to prevent and treat infectious diseases and cancer. ➢ A third-generation hepatitis B vaccine (Sci-B-Vac™) that is currently marketed in 15 countries around the world. VBI is planning to meet with regulators from the FDA and …

  • SNGX Announces Positive Results of a Heat Stable Ebola Vaccine Formulation Zacks Small Cap Research - Tue, Jul 19, 2016 1:30 PM EDT

    On July 18, 2016, Soligenix (SNGX) announced positive preliminary proof-of-concept results from a heat stable subunit Ebola vaccine. This is a collaboration with Axel Lehrer, PhD of the Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine (JABSOM), University of Hawaiʻi …

  • LMD.V: Q2 Revenue Preannouncement Inline With Our Estimate Zacks Small Cap Research - Mon, Jul 18, 2016 2:45 PM EDT

    By Brian Marckx, CFA OTC:LEDIF TSX:LMD.V Q2 2016 Revenue Preannouncement : LED Medical (TSX:LMD.V) (OTC:LEDIF) preannounced Q2 2016 revenue of $3.7M, inline with our $3.6M estimate and representing growth ...

  • BCLI: Phase 2 ALS Trial Shows Clinical Benefit From NurOwn™ Treatment Zacks Small Cap Research - Mon, Jul 18, 2016 1:30 PM EDT

    The data show that patients treated with NurOwn™ were more likely to see a decrease in the rate of decline as measured by the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) compared to those treated with placebo. ALS is a rapidly progressing neurodegenerative disease whereby the nerve cells in the brain …

  • AVIR: Resuming Phase 2a RSV Trial Zacks Small Cap Research - Thu, Jul 14, 2016 4:00 PM EDT

    BTA585, an oral fusion protein inhibitor received Fast Track designation by the FDA in Feb 2016.  Management initiated the Phase 2a RSV challenge efficacy study in the beginning of April 2016.  The Phase 2a double-blind, placebo-controlled study is designed to evaluate the safety, pharmacokinetics, and antiviral activity …

  • BMRA: More Positive Clarity on InFoods' FDA Pathway Zacks Small Cap Research - Wed, Jul 13, 2016 10:20 AM EDT

    FDA Determines InFoods is ‘Nonsignificant Risk’ Device: Eliminates Need for IDE Approval, Supports Expectation of De Novo Pathway… 

  • The management of Midwest Energy Emissions (MEEC) held a conference call yesterday to announce preliminary second quarter revenue of at least $9.2 million and to provide full year 2016 revenue guidance of at least $30 million. With its successful implementation of SEA™ Technology, Midwest Energy Emissions is gaining further …

  • CYNA: Business Update Zacks Small Cap Research - Mon, Jul 11, 2016 3:00 PM EDT

    By Anita Dushyanth, PhD NASDAQ:CYNA There have been several events since our last update including progress on Phase 3 efficacy study, addition to the board of directors and presentation of clinical data ...

  • ELIO: Zacks Unveils E1-A; E1-B, E1-C and E1-D in process Zacks Small Cap Research - Mon, Jul 11, 2016 11:30 AM EDT

    The ceremony took place at the company’s Pilot Operations Center in Livonia, Michigan in front of more than 200 automotive supplier executives and engineers. Management is planning to build a total of 23 E-Series vehicles to test the safety, aerodynamics and durability characteristics of the Elio’s design.

  • BNKL: RATULS Study Progress, IMT Pro Formas Zacks Small Cap Research - Thu, Jul 7, 2016 12:30 PM EDT

    By Brian Marckx, CFA OTC:BNKL Bionik (OTC:BNKL) recently changed their fiscal year end from December 31 to March 30.  Bionik  announced fourth quarter financial results and provided an operational update.  ...

  • FCHS: New CFO appointed Zacks Small Cap Research - Thu, Jul 7, 2016 10:50 AM EDT

    By Ian Gilson PhD, CFA OTC:FCHS On July 6, 2016 First Choice (OTC:FCHS) announced the appointment of Mr. T. K. Skeldon as CFO.    Mr. Skeldon has extensive experience as a CFO in the healthcare industry ...

  • AKTS: Q4 2016 Results Show Continued Progress Toward Commercialization Zacks Small Cap Research - Tue, Jul 5, 2016 11:30 AM EDT

    By Lisa Thompson OTC:AKTS Akoustis (OTC:AKTS) released its March 31, 2016 10K with results being in line with forecasts. The company ended the year having lost $3.7 million or $0.32 per share. EBITDA was ...

  • AEMD: U.S. Clinical Trial Progressing, ATM Financing Zacks Small Cap Research - Tue, Jul 5, 2016 9:45 AM EDT

    By Brian Marckx, CFA NASDAQ:AEMD Fiscal Q4 2016 Financials, Operational Update  Aethlon (NASDAQ:AEMD) reported financial results for their fourth quarter 2016 and provided and operational update.  Financial ...

  • FNJN: Company Books $565,000 License Deal At Quarter End Zacks Small Cap Research - Fri, Jul 1, 2016 9:00 AM EDT

    On June 28, 2016, Finjan (FNJN) squeezed another license deal for $565,000 into the quarter resulting in our need to raise revenue and earnings estimates for Q2. This deal was with an unnamed European-based provider of cloud and on-premise cybersecurity solutions and it has already been paid. Finjan is positioned to grow …

  • LPCN: FDA Issues CRL for Tlando Zacks Small Cap Research - Thu, Jun 30, 2016 2:30 PM EDT

    By John Vandermosten, CFA NASDAQ:LPCN On June 29, 2016, Lipocine Inc. (NASDAQ:LPCN) announced that the Food and Drug Administration (FDA) had issued a Complete Response Letter (CRL) for LPCN 1021 (Tlando).  ...

  • RVX: Initiating with CAD$5.00 Target: Successful BETonMACE Provides Material Upside Zacks Small Cap Research - Thu, Jun 30, 2016 12:00 PM EDT

    Resverlogix is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production.  Novel compounds arising from Resverlogix's epigenetic drug development platform function by inhibiting Bromodomain and Extra Terminal domain (BET) proteins and have the potential to impact multiple …

  • CYRX: Clinical Trial Base Ramping, Expect Significant Contribution in 2017 Zacks Small Cap Research - Thu, Jun 30, 2016 10:35 AM EDT

    By Brian Marckx, CFA NASDAQ:CYRX Q4 Fiscal 2016: Revenue Inline.  Clinical Trial Pipeline Growth Ramping, Expect Significant Contribution in 2017… CryoPort (NASDAQ:CYRX) reported financial results for ...

  • SANW : Providing sunflower seed varieties to the two largest markets in the world. Zacks Small Cap Research - Wed, Jun 29, 2016 11:00 AM EDT

    By Ian Gilson, PhD, CFA NASDAQ:SANW SANW (NASDAQ:SANW) has announced it has signed a new license agreement for the production and marketing of two sunflower varieties for the markets of the Ukraine (the ...

  • CBMX: Largest Study To-Date Further Supports Superiority of CMA Zacks Small Cap Research - Tue, Jun 28, 2016 2:30 PM EDT

    While several studies over the last number of years, including the widely cited Reddy et al and Wapner et al studies which have positively influenced reimbursement policy, have all indicated  that chromosomal microarray analysis (CMA) is the preferred genetic testing modality versus karyotyping due to the former's proven …

  • CFRX: New PK/PD and Microbiologic Data Presented on CF-301 Zacks Small Cap Research - Mon, Jun 27, 2016 2:30 PM EDT

    A lysin is a naturally occurring anti-bacterial hydrolytic enzyme that is produced by bacteriophages, which are virus’ that infect and kill bacteria. Lysins are highly evolved enzymes that are able to target one of the five bonds in peptidoglycan (murein), the main component of bacterial cell walls. The N-terminal domain …

  • Opiant Pharmaceuticals (OPNT) is a specialty pharmaceutical company developing treatments for substance use, binge eating disorder, and cocaine use disorder based on the company’s expertise in opioid receptor antagonists. Examples of opioid medications include hydrocodone (Vicodin®), oxycodone (OxyContin®), morphine, and …

  • PBSV: Q2 Inline. Positive Net Income, Cash Flow Continues. Reiterate $2/Share Target Zacks Small Cap Research - Thu, Jun 16, 2016 10:30 AM EDT

    By Brian Marckx, CFA OTC:PBSV Fiscal Q2 2016 Results: Inline With Estimates.  Continue to Generate Positive Cash Flow, Net Income…   Pharma-Bio Serv (OTC:PBSV) reported financial results for their second ...

  • FCHS: Two new doctors on board. Increasing estimates for 4Q16. Zacks Small Cap Research - Thu, Jun 16, 2016 10:00 AM EDT

    Dr. Raymond J. DeLorenzi has joined FCMG, thus completing the expected roster as discussed previously. The DeLorenzi Orthopaedic Center is a single doctor practice in Viera, FL and is 13 miles from Marina Towers. Dr. DeLorenzi is affiliated with a number of hospitals and medical centers in the Viera area so it should …

  • GGAC: Garnero Group Acquisition Company Amends Merger Agreement Zacks Small Cap Research - Wed, Jun 15, 2016 2:15 PM EDT

    Today, Garnero Group Acquisition Company (GGAC) announced that definitive investment agreement with Grupo Colombo has been amended again. Approximately 64% of Grupo Colombo's unsecured creditors have approved the restructuring plan, which still needs to be confirmed by the Brazilian courts.

  • VIVMF: Several Catalysts Set To Further Steepen System Placement Rate Zacks Small Cap Research - Wed, Jun 15, 2016 9:00 AM EDT

    In January VIVMF penned a distribution agreement with Dynamic Medical Technologies for certain Asian countries.  The agreement includes minimum purchase quotas of 47 systems in 2016, 75 in 2017 and 109 in 2018.  Growth will be further facilitated by the system gaining regulatory clearance in more countries.  In March Viveve …

  • WEYL: Zacks Initiation Report - Asian DIY App Maker Expanding Geographically Zacks Small Cap Research - Tue, Jun 14, 2016 1:10 PM EDT

    Today we are initiating coverage of Weyland Tech Inc (WEYL). Weyland markets a “do-it-yourself” mobile app creation platform as SaaS in Singapore. The CreateApp platform is now offered in twelve languages: English, Chinese, Japanese, Korean, Bahasa Malay, Bahasa Indonesia, Thai, Hindi, Vietnamese, Spanish, French, and …

  • The data presented confirms that the 5.6 mg dose of TNX-102 SL was effective at reducing the symptoms of military-related Post Traumatic Stress Disorder (PTSD) and was well tolerated. Below we provide an overview of the data presented and provide context in relation to previous PTSD studies. PTSD is a psychiatric disorder …

  • ELIO: Zacks Small Cap Research Now Covers Elio Motors - Price Target of $51 Zacks Small Cap Research - Mon, Jun 13, 2016 2:00 PM EDT

    Elio Motors (ELIO) is in the process of designing, developing and soon-to-be manufacturing an ultra-efficient, low-cost, three-wheeled, two-person vehicle.  With attractive performance, safety, fuel economy and aerodynamic styling characteristics, the Elio has the potential to become a game-changer leading to broad market …

  • By Grant Zeng NASDAQ:CASI The Poster Presentation During the 2016 ASCO meeting held June 3-7 at Chicago, CASI (NASDAQ:CASI) made a poster presentation about its lead candidate ENMD-2076 for ovarian clear ...

  • PURE: Update on Fiscal Third Quarter 2016 Financials Zacks Small Cap Research - Fri, Jun 10, 2016 10:55 AM EDT

    By Grant Zeng, CFA NASDAQ:PURE Total revenue for Pure Biosciences (NASDAQ:PURE) fiscal 3Q16 ended April 30 was $0.40 million, as compared to $0.11 million for the same period of 2015, an increase of 269.7%. ...

  • PBIO: Update on First Quarter 2016 Financials Zacks Small Cap Research - Wed, Jun 8, 2016 1:05 PM EDT

    By Grant Zeng, CFA Update on First Quarter 2016 Financials OTC:PBIO Total revenue for Pressure BioSciences (OTC:PBIO) for 1Q16 was $0.51 million, as compared to $0.44 million during the three months ended ...

  • ATOS: New Financial Commitment Secured Zacks Small Cap Research - Wed, Jun 8, 2016 11:15 AM EDT

    New Financial Commitment Secured By Grant Zeng, CFA NASDAQ:ATOS There was no revenue recorded for the 1Q16 for Atossa (NASDAQ:ATOS) due to the sale of the NRLBH in December 2015. The NLRBH had total net ...

  • TENX: Phase 3 Readout Expected by Summer’s End Zacks Small Cap Research - Wed, Jun 8, 2016 11:00 AM EDT

    By John Vandermosten, CFA NASDAQ:TENX Tenax Reports First Quarter 2016 Results On May 19, 2015, Tenax Therapeutics, Inc. (NASDAQ:TENX) reported financial results for the three month period ending March ...

  • ANTB: Once Weekly Diabetes Therapy: Investors Needed Zacks Small Cap Research - Wed, Jun 8, 2016 9:45 AM EDT

    On May 16, 2016, AntriaBio, Inc. (ANTB) filed its Form 10-Q reporting financial results for the third quarter of fiscal year 2016 ending March 31, 2016.  No revenues were generated in the quarter. Research and development costs were approximately $2.3 million in 3Q:16 compared to $1.3 million in the same quarter in the …

  • CZO.V: Ceapro Reports Accelerating Growth Zacks Small Cap Research - Wed, Jun 8, 2016 9:25 AM EDT

    By John Vandermosten, CFA TSX:CZO.V On May 18, 2016, Ceapro Inc. (TSX:CZO.V) announced first quarter 2016 revenues and earnings.  Sales increased by 137% in the first quarter, achieving a company record ...

  • MDGN Adds Another High-Potential Orphan Candidate Zacks Small Cap Research - Tue, Jun 7, 2016 4:30 PM EDT

    By Brian Marckx, CFA NYSE:MDGN Initiating Severe Pediatric Onset Inflammatory Bowel Disease Program. Second CHOP Collaboration Yesterday (6/7) Medgenics (NYSE:MDGN) announced that, in collaboration with ...

  • CTS outlines restructuring costs and benefits. Zacks Small Cap Research - Tue, Jun 7, 2016 4:00 PM EDT

    The company (CTS) has announced that it will phase out production at the Elkhart, Indiana manufacturing plant and use the location for a research and development center. CTS's corporate HQ is located in Elkhart, Indiana but its administrative offices are in a 37,300 sq.ft. leased facility in Lisle, Illinois. The Elkhart …

  • Revenue came in at ~$400,000 but widely missed our estimate by ~50%.  The domestic market (Canada) revenue decreased ~50% as compared to the same period in 2015 offsetting more than ~50% bump in international regions.  The U.S. revenue jumped by 1700% from Q1 2015.  Theralase is focused on training its marketing team to …

  • GOVX: GeoVax: Entering into HBV Market Zacks Small Cap Research - Tue, Jun 7, 2016 11:15 AM EDT

    By Grant Zeng, CFA OTC:GOVX On Jun 6, 2016, GeoVax (OTC:GOVX) announced the launch of a program to develop a therapeutic vaccine for treatment of chronic Hepatitis B infections (HBV). This announcement ...

  • GeoVax: Entering into HBV Market Zacks Small Cap Research - Tue, Jun 7, 2016 11:15 AM EDT

    GeoVax: Entering into HBV Market On Jun 6, 2016, GeoVax  OTCOB:GOVX announced the launch of a program to develop a therapeutic vaccine for treatment of chronic Hepatitis B infections (HBV). This announcement ...

  • AKTS: Zacks Company Report Company Announces Industry Leading Product Performance Zacks Small Cap Research - Tue, Jun 7, 2016 10:30 AM EDT

    In May at an industry conference, Akoustis reported that its 3.4GHz BAW resonators, constructed from single crystal undoped aluminum nitride (AlN) piezoelectric material, showed a record high K-squared of 12.5%. In comparison, resonators currently on the market show K-squared performance from undoped polycrystalline AlN …

  • FCHS: Dr. Kenneth Sands joins First Choice Medical Group Zacks Small Cap Research - Sun, Jun 5, 2016 4:00 PM EDT

    By Ian Gilson, PhD, CFA OTC:FCHS As discussed during the 1Q16 conference call the first of two doctors expected to join FCMG is now on board.   First Choice (OTC:FCHS)  has announced that Dr. Kenneth C. ...

  • As expected, the company did not report any revenues during the quarter. The company reported a net loss of $0.5 million, which was comprised of $0.5 million in R&D expenses, $0.2 million in G&A expenses, and other income of $0.3 million. Total cash burn for the first quarter was $0.9 million, and the company exited the …

  • CTSO: Fresenius Commences Sales, DSMB Recommends Continuation of REFRESH I Zacks Small Cap Research - Fri, Jun 3, 2016 10:30 AM EDT

    By Brian Marckx, CFA NYSE:FMS NASDAQ:CTSO Fresenius Commences Commercialization . While delayed from initial expectations, the long-awaited announcement that Fresenius (NYSE:FMS) has started selling CytoSorb ...

  • EYEG: Positive Cataract Surgery Results. Pivotal Study Could Commence By Year-End Zacks Small Cap Research - Thu, Jun 2, 2016 3:45 PM EDT

    By Brian Marckx, CFA NASDAQ:EYEG Positive Cataract Surgery Top-Line Results… Yesterday (6/1) EyeGate (NASDAQ:EYEG) announced positive top-line results from its ongoing phase Ib/IIa post-cataract surgery ...

  • CANF: Update on First Quarter Financials ended March 31, 2016 Zacks Small Cap Research - Wed, Jun 1, 2016 3:11 PM EDT

    The company did not record any revenues during the three months ended March 31, 2015. The increase was primarily due to costs associated with preparations of the CF101 Phase III studies in the treatment of rheumatoid arthritis and psoriasis. In September, 2015, the company closed a registered direct offering with institutional …

  • CPXX: Jazz Acquires Celator for $30.25 per Share Zacks Small Cap Research - Wed, Jun 1, 2016 10:55 AM EDT

    By Grant Zeng, CFA NASDAQ:CPXX Jazz Acquires Celator for $30.25 per Share On May 31, 2016, Jazz Pharmaceuticals plc (JAZZ) and Celator Pharmaceuticals (NASDAQ:CPXX) announced that they have entered into ...

Next >>